2024 Fall Conference | C1 - Opening Keynote: Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD)

Date Friday 10/25/24

Time 08:00 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Topic(s) Autoimmune Neurology, Multiple Sclerosis

Learning Objectives This keynote session will highlight the hallmark clinical and MRI features of MOG antibody-associated disease (MOGAD) and summarize its 2023 diagnostic criteria, offer guidance on when to order and how to interpret MOG-antibody test results, and review the current treatment approach and clinical trials available.

CME Available 1.00 CME credit

Core Competencies Medical Knowledge

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
08:00 AM - 09:00 AM PDT	Speaker	Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD) Eoin P. Flanagan, MBBCh, FAAN

Faculty Disclosures
Eoin P. Flanagan, MBBCh, FAAN	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.

��ɫ��

��ɫ��